The new National Center for Advancing Translational Sciences planned for the US National Institutes of Health intends to help transform biological findings into new therapeutic products. But if taxpayer funding of risky biomedical research translates into lucrative new medicines, the public should share in the economic benefits as well.
No takes yet. Share an insight, caveat, or question.
Avorn et al. (2011) studied this question.
Synapse has enriched 5 related papers. Consider them for comparative context: